

Supplementary Table 1. Treatments available in IMPRESS-Norway

Drug name	Mechanism of action	Available since*	Company
Alectinib	ALK and RET inhibitor	April 2021	Roche
Atezolizumab	PD-L1 inhibitor	April 2021	Roche
Bevacizumab	VEGFR inhibitor	April 2021	Roche
Cobimetinib	MEK inhibitor	April 2021	Roche
Entrectinib	ALK, ROS-1 and NTRK inhibitor	April 2021	Roche
Trastuzumab and pertuzumab	Her-2 inhibitor	April 2021	Roche
Vemurafenib	BRAF inhibitor	April 2021	Roche
Vismodegib	Hedgehog pathway inhibitor	April 2021	Roche
Dabrafenib	BRAF inhibitor	January 2022	Novartis
Trametinib	MEK inhibitor	January 2022	Novartis
Alpelisib	PI3K inhibitor	June 2022	Novartis
Fulvestrant	Estrogen receptor inhibitor	June 2022	Novartis
Olaparib	PARP inhibitor	June 2022	Astra Zeneca
Imatinib	Abl, c-Kit and PDGFR inhibitor	June 2022	Generic
Capmatinib	MET inhibitor	November 2022	Novartis
Pemigatinib	FGFR inhibitor	February 2023	Incyte
Selpercatinib	RET inhibitor	February 2023	Eli Lilly
Bortezomib	Proteasome inhibitor	February 2023	Generic
Tepotinib	MET inhibitor	March 2023	Merck
Melphalan	Alkylating agent	June 2023	Generic
Actinomycin D and hydroxyurea	Cytotoxic antibiotic and antimetabolite	August 2023	Generic
Ceritinib	ALK inhibitor	Expected December 2023	Generic
Dostarlimab	PD-1 receptor inhibitor	Expected December 2023	GSK
Niraparib	PARP inhibitor	Expected December 2023	GSK

*Available since refers to time point from which eligible patients could start treatment on the drug.

Supplementary Table 2. Baseline characteristics of the patients included in screening and treatment phase of the study

	Screening phase (n=1,167)	Treatment phase (n=170)
Age in years, median (range)	58 (18-84)	60 (19-79)
Gender, n (%)		
Male	572 (49%)	76 (45%)
Female	595 (51%)	94 (55%)
ECOG performance status, n (%)		
ECOG 0	371 (32%)	61 (36%)
ECOG 1	416 (36%)	78 (45%)
ECOG 2	130 (11%)	30 (18 %)
Unknown*	250 (21%)	1 (<1%)
Tumor types, n (%)		
Colorectal Cancer	154 (13%)	16 (9%)
Cholangiocarcinoma	83 (7%)	18 (11%)
NSCLC**	78 (7%)	14 (8%)
Breast Cancer	72 (6%)	4 (2%)
GBM***, IDH wildtype	53 (5%)	9 (5%)
Ovarian carcinoma	46 (4%)	10 (6%)
Thyroid carcinoma	21 (2%)	8 (5%)
Bladder	19 (2%)	6 (4%)
Other	641 (54%)	85 (50%)

* Registration in in electronic case report form (eCRF) is ongoing

** Non-small cell lung cancer

*** Glioblastoma